The Role of Cytotoxic Therapy with Hematopoietic Stem Cell Transplantation in the Therapy of Acute Myelogenous Leukemia in Adults: An Evidence-Based Review
Tóm tắt
Từ khóa
Tài liệu tham khảo
Hahn, 2001, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of diffuse large cell B-cell non-Hodgkin's lymphoma: an evidence-based review, Biol Blood Marrow Transplant, 7, 308, 10.1016/S1083-8791(01)80003-3
Hahn, 2003, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of multiple myeloma: an evidence-based review, Biol Blood Marrow Transplant, 9, 4, 10.1053/bbmt.2003.50002
Hahn, 2005, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in children: an evidence-based review, Biol Blood Marrow Transplant, 11, 823, 10.1016/j.bbmt.2005.08.035
Hahn, 2006, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review, Biol Blood Marrow Transplant, 12, 1, 10.1016/j.bbmt.2005.10.018
Oliansky, 2007, The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in children: an evidence-based review, Biol Blood Marrow Transplant, 13, 1, 10.1016/j.bbmt.2006.10.024
Jones, 2005, The evolution of the evidence-based review: evaluating the science enhances the art of medicine-statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation, Biol Blood Marrow Transplant, 11, 819, 10.1016/j.bbmt.2005.06.005
Levi, 2004, Meta-analysis of autologous bone marrow transplantation versus chemotherapy in adult patients with acute myeloid leukemia in first remission, Leuk Res, 28, 605, 10.1016/j.leukres.2003.10.029
Nathan, 2004, Consolidation therapy with autologous bone marrow transplantation in adults with acute myeloid leukemia: a meta-analysis, J Natl Cancer Inst, 96, 38, 10.1093/jnci/djh003
Reiffers, 1996, Allogeneic vs autologous stem cell transplantation vs chemotherapy in patients with acute myeloid leukemia in first remission: the BGMT 87 study, Leukemia, 10, 1874
Harousseau, 1997, Comparison of autologous bone marrow transplantation and intensive chemotherapy as postremission therapy in adult acute myeloid leukemia. The Groupe Ouest Est Leucemies Aigues Myeloblastiques (GOELAM), Blood, 90, 2978
Miggiano, 1996, Autologous bone marrow transplantation in late first complete remission improves outcome in acute myelogenous leukemia, Leukemia, 10, 402
Burnett, 1998, Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties, Lancet, 351, 700, 10.1016/S0140-6736(97)09214-3
Rohatiner, 2000, High-dose treatment with autologous bone marrow support as consolidation of first remission in younger patients with acute myelogenous leukaemia, Ann Oncol, 11, 1007, 10.1023/A:1008333903220
Cassileth, 1998, Chemotherapy compared with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission, N Engl J Med, 339, 1649, 10.1056/NEJM199812033392301
Bassan, 1998, Outcome assessment of age group-specific (+/− 50 years) post-remission consolidation with high-dose cytarabine or bone marrow autograft for adult acute myelogenous leukemia, Haematologica, 83, 627
Yanada, 2005, Efficacy of allogeneic hematopoietic stem cell transplantation depends on cytogenetic risk for acute myeloid leukemia in first disease remission, Cancer, 103, 1652, 10.1002/cncr.20945
Cornelissen, 2007, Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?, Blood, 109, 3658, 10.1182/blood-2006-06-025627
Burnett, 2002, The value of allogeneic bone marrow transplant in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial, Br J Haematol, 118, 385, 10.1046/j.1365-2141.2002.03724.x
Gale, 1996, HLA-identical sibling bone marrow transplants vs chemotherapy for acute myelogenous leukemia in first remission, Leukemia, 10, 1687
Cassileth, 1992, Escalating the intensity of post-remission therapy improves the outcome in acute myeloid leukemia: the ECOG experience. The Eastern Cooperative Oncology Group, Leukemia, 6, 116
Schiller, 1992, Bone marrow transplantation versus high-dose cytarabine-based consolidation chemotherapy for acute myelogenous leukemia in first remission, J Clin Oncol, 10, 41, 10.1200/JCO.1992.10.1.41
Willemze, 1991, Bone marrow transplantation or chemotherapy as post-remission treatment of adult acute myelogenous leukemia, Ann Hematol, 62, 59, 10.1007/BF01714901
Archimbaud, 1994, Prospective genetically randomized comparison between intensive postinduction chemotherapy and bone marrow transplantation in adults with newly diagnosed acute myeloid leukemia, J Clin Oncol, 12, 262, 10.1200/JCO.1994.12.2.262
Mohty, 2005, The role of reduced intensity conditioning allogeneic stem cell transplantation in patients with acute myeloid leukemia: a donor vs no donor comparison, Leukemia, 19, 916, 10.1038/sj.leu.2403770
Gale, 1996, Chemotherapy versus transplants for acute myelogenous leukemia in second remission, Leukemia, 10, 13
Ringden, 2000, Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?, Br J Haematol, 111, 1130, 10.1046/j.1365-2141.2000.02493.x
Lazarus, 2006, Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research, Br J Haematol, 132, 755, 10.1111/j.1365-2141.2005.05947.x
Suciu, 2003, Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMA AML-10 trial, Blood, 102, 1232, 10.1182/blood-2002-12-3714
Carella, 1992, Autologous and allogeneic bone marrow transplantation in acute myeloid leukemia in first complete remission: an update of the Genoa experience with 159 patients, Ann Hematol, 64, 128, 10.1007/BF01697399
Singhal, 2003, Haploidentical vs autologous hematopoietic stem cell transplantation in patients with acute leukemia beyond first remission, Bone Marrow Transplant, 31, 889, 10.1038/sj.bmt.1704031
Mitus, 1995, Improved survival for patients with acute myelogenous leukemia, J Clin Oncol, 13, 560, 10.1200/JCO.1995.13.3.560
Cassileth, 1993, Autologous bone marrow transplant in acute myeloid leukemia in first remission, J Clin Oncol, 11, 314, 10.1200/JCO.1993.11.2.314
Lowenberg, 1990, Autologous bone marrow transplantation in acute myeloid leukemia in first remission: results of a Dutch prospective study, J Clin Oncol, 8, 287, 10.1200/JCO.1990.8.2.287
Sierra, 1996, Feasibility and results of bone marrow transplantation after remission induction and intensification chemotherapy in de novo acute myeloid leukemia. Catalan Group for Bone Marrow Transplantation, J Clin Oncol, 14, 1353, 10.1200/JCO.1996.14.4.1353
Reiffers, 2000, Autologous blood cell vs marrow transplantation for acute myeloid leukemia in complete remission: an EBMT retrospective analysis, Bone Marrow Transplant, 25, 1115, 10.1038/sj.bmt.1702389
Sirohi, 2004, Reassessing autotransplantation for acute myeloid leukaemia in first remission—a matched pair analysis of autologous marrow vs peripheral blood stem cells, Bone Marrow Transplant, 33, 1209, 10.1038/sj.bmt.1704511
Vey, 2004, Autologous stem cell transplantation for acute myelogenous leukemia in first complete remission: a 6-year follow-up study of 101 patients from a single institution, Bone Marrow Transplant, 33, 177, 10.1038/sj.bmt.1704326
Miller, 2001, The effect of graft purging with 4-hydroperoxycyclophosphamide in autologous bone marrow transplantation for acute myelogenous leukemia, Exp Hematol, 29, 1336, 10.1016/S0301-472X(01)00732-9
Gorin, 1990, Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging, Blood, 75, 1606, 10.1182/blood.V75.8.1606.1606
Chao, 1993, Busulfan/Etoposide-initial experience with a new preparatory regimen for autologous bone marrow transplantation in patients with acute nonlymphoblastic leukemia, Blood, 81, 319, 10.1182/blood.V81.2.319.319
McMillan, 1990, High-dose chemotherapy and autologous bone marrow transplantation in acute myeloid leukemia, Blood, 76, 480, 10.1182/blood.V76.3.480.480
Kim, 2004, Autologous stem cell transplantation using modified TAM or combination of triple-alkylating agents conditioning regimens as one of the post-remission treatments in patients with adult acute myeloid leukemia in first complete remission, Bone Marrow Transplant, 34, 215, 10.1038/sj.bmt.1704556
Mollee, 2004, Long-term outcome after intensive therapy with etoposide, melphalan, total body irradiation and autotransplant for acute myeloid leukemia, Bone Marrow Transplant, 33, 1201, 10.1038/sj.bmt.1704506
Gorin, 2000, Feasibility and recent improvement of autologous stem cell transplantation for acute myelocytic leukaemia in patients over 60 years of age: importance of the source of stem cells, Br J Haematol, 110, 887, 10.1046/j.1365-2141.2000.02265.x
Gorin, 1999, Importance of marrow dose on posttransplant outcome in acute leukemia: models derived from patients autografted with mafosfamide-purged marrow at a single institution, Experimental Hematology, 27, 1822, 10.1016/S0301-472X(99)00121-6
Linker, 1998, Autologous bone marrow transplantation for acute myeloid leukemia using 4-hydroperoxycyclophosphamide-purged bone marrow and the busulfan/etoposide preparative regimen: a follow-up report, Bone Marrow Transplant, 22, 865, 10.1038/sj.bmt.1701436
Isnard, 2001, Improved efficiency of remission induction facilitates autologous BMT harvesting and improves overall survival in adults with AML: 108 patients treated at a single institution, Bone Marrow Transplant, 27, 1045, 10.1038/sj.bmt.1703031
Jourdan, 2005, One versus 2 high-dose cytarabine-based consolidation before autologous stem cell transplantation for young acute myeloblastic leukaemia patients in first complete remission, Br J Haematol, 129, 403, 10.1111/j.1365-2141.2005.05470.x
Meloni, 1996, BAVC regimen and autograft for acute myelogenous leukemia in second complete remission, Bone Marrow Transplant, 18, 693
Stein, 1996, In vivo purging with high-dose cytarabine followed by high-dose chemoradiotherapy and reinfusion of unpurged bone marrow for adult acute myelogenous leukemia in first complete remission, J Clin Oncol, 14, 2206, 10.1200/JCO.1996.14.8.2206
Linker, 2000, Autologous stem cell transplantation for acute myeloid leukemia in first remission, Biol Blood Marrow Transplant, 6, 50, 10.1016/S1083-8791(00)70052-8
Pavlovsky, 1998, Autologous peripheral blood progenitor cell transplantation mobilized with high-dose cytarabine in acute myeloid leukemia in first complete remission, Ann Oncol, 9, 151, 10.1023/A:1008271624978
Hegenbart, 2006, Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors, J Clin Oncol, 24, 444, 10.1200/JCO.2005.03.1765
Sayer, 2003, Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia: disease status by marrow blasts is the strongest prognostic factor, Bone Marrow Transplant, 31, 1089, 10.1038/sj.bmt.1704062
Wagner, 2005, Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial, Lancet, 366, 733, 10.1016/S0140-6736(05)66996-6
Hale, 1998, Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection, Blood, 92, 4581, 10.1182/blood.V92.12.4581
Marmont, 1991, T-cell depletion of HLA-identical transplants in leukemia, Blood, 78, 2120, 10.1182/blood.V78.8.2120.2120
Garderet, 2003, Patients with acute lymphoblastic leukaemia allografted with a matched unrelated donor may have a lower survival with a peripheral blood stem cell graft compared to bone marrow, Bone Marrow Transplant, 31, 23, 10.1038/sj.bmt.1703778
Ringden, 2002, Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia, J Clin Oncol, 20, 4655, 10.1200/JCO.2002.12.049
Michallet, 2000, Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Societe Francaise de Greffe de Moelle (SFGM), Bone Marrow Transplant, 26, 1157, 10.1038/sj.bmt.1702690
Stelljes, 2005, Conditioning with 8-Gy total body irradiation and fludarabine for allogeneic hematopoietic stem cell transplantation in acute myeloid leukemia, Blood, 106, 3314, 10.1182/blood-2005-04-1377
Greinix, 2002, Factors affecting long-term outcome after allogeneic haematopoietic stem cell transplantation for acute myelogenous leukaemia: a retrospective study of 172 adult patients reported to the Austrian Stem Cell Transplantation Registry, Br J Haematol, 117, 914, 10.1046/j.1365-2141.2002.03532.x
Sierra, 2000, Unrelated donor marrow transplantation for acute myeloid leukemia: an update of the Seattle experience, Bone Marrow Transplant, 26, 397, 10.1038/sj.bmt.1702519
Cook, 2006, The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy, Biol Blood Marrow Transplant, 12, 293, 10.1016/j.bbmt.2005.10.019
Bunjes, 2002, Re-labeled anti-CD66 monoclonal antibody in stem cell transplantation for patients with high-risk acute myeloid leukemia, Leuk Lymphoma, 43, 2125, 10.1080/1042819021000033015
Rocha, 2002, Relevance of bone marrow cell dose on allogeneic transplantation outcomes for patients with acute myeloid leukemia in first complete remission: results of a European survey, J Clin Oncol, 20, 4324, 10.1200/JCO.2002.11.058
Tallman, 2000, Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission, Blood, 96, 1254
Clift, 1992, Allogeneic marrow transplantation during untreated first relapse of acute myeloid leukemia, J Clin Oncol, 10, 1723, 10.1200/JCO.1992.10.11.1723
Mehta, 2002, Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?, Bone Marrow Transplant, 29, 853, 10.1038/sj.bmt.1703545
Brown, 1996, High-dose etoposide, cyclophosphamide and total body irradiation with allogeneic bone marrow transplantation for resistant acute myeloid leukemia: a study by the North American Marrow Transplant Group, Leuk Lymphoma, 22, 271, 10.3109/10428199609051758
Greinix, 1996, Long-term leukemia-free survival after allogeneic marrow transplantation in patients with acute myelogenous leukemia, Ann Hematol, 72, 53, 10.1007/BF00641308
Zikos, 1998, Low transplant mortality in allogeneic bone marrow transplantation for acute myeloid leukemia: a randomized study of low-dose cyclosporin versus low-dose cyclosporin and low-dose methotrexate, Blood, 91, 3503, 10.1182/blood.V91.9.3503
Bibawi, 2001, Thiotepa, busulfan, and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced myelodysplastic syndrome and acute myelogenous leukemia, Am J Hematol, 67, 227, 10.1002/ajh.1121
Frassoni, 1991, Eradication of leukaemic marrow and prevention of leukaemia relapse with total body irradiation and bone marrow transplantation, Med Oncol Tumor Pharmacother, 8, 189, 10.1007/BF02987179
Ball, 2000, Autologous bone marrow transplantation for acute myeloid leukemia in remission or first relapse using monoclonal antibody-purged marrow: results of phase II studies with long-term follow-up, Bone Marrow Transplant, 25, 823, 10.1038/sj.bmt.1702229
Blaise, 1992, Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-Cytoxan versus Cytoxan-total body irradiation as preparative regimen: a report from the Group d'Etudes de la Greffe de Moelle Osseuse, Blood, 79, 2578, 10.1182/blood.V79.10.2578.bloodjournal79102578
Farag, 2005, High-dose busulfan, cyclophosphamide, and etoposide does not improve outcome of allogeneic stem cell transplantation compared to BuCy2 in patients with acute myeloid leukemia, Bone Marrow Transplant, 35, 653, 10.1038/sj.bmt.1704867
Resbeut, 1995, Fractionated or single-dose total body irradiation in 171 acute myeloblastic leukemias in first complete remission: is there a best choice? SFGM. Societe Francaise de Greffe de Moelle, Int J Radiat Oncol Biol Phys, 31, 509, 10.1016/0360-3016(94)00446-R
Litzow, 2002, Comparison of outcome following allogeneic bone marrow transplantation with cyclophosphamide-total body irradiation versus busulphan-cyclophosphamide conditioning regimens for acute myelogenous leukaemia in first remission, Br J Haematol, 119, 1115, 10.1046/j.1365-2141.2002.03973.x
Bacigalupo, 2000, The combined effect of total body irradiation (TBI) and cyclosporin A (CyA) on the risk of relapse in patients with acute myeloid leukaemia undergoing allogeneic bone marrow transplantation, Br J Haematol, 108, 99, 10.1046/j.1365-2141.2000.01809.x
Schaap, 1997, Outcome of transplantation for standard-risk leukaemia with grafts depleted of lymphocytes after conditioning with an intensified regimen, Br J Haematol, 98, 750, 10.1046/j.1365-2141.1997.d01-3499.x
Shimoni, 2006, Allogeneic hematopoietic stem-cell transplantation in AML and MDS using myeloablabtive versus reduced-intensity conditioning: the role of dose intensity, Leukemia, 20, 322, 10.1038/sj.leu.2404037
de Lima, 2004, Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation, Blood, 104, 865, 10.1182/blood-2003-11-3750
Kroger, 2000, Dose-dependent effect of etoposide in combination with busulfan plus cyclophosphamide as conditioning for stem cell transplantation in patients with acute myeloid leukemia, Bone Marrow Transplant, 26, 711, 10.1038/sj.bmt.1702598
Collins, 1997, Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation, J Clin Oncol, 15, 433, 10.1200/JCO.1997.15.2.433
Eapen, 2004, Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant, Bone Marrow Transplant, 34, 721, 10.1038/sj.bmt.1704645
De Witte, 1997, Autologous bone marrow transplantation for patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS. Chronic and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation, Blood, 90, 3853
Kroger, 2006, Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome, Bone Marrow Transplant, 37, 183, 10.1038/sj.bmt.1705226
Frassoni, 1994, Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT), Leukemia, 8, 924
Abdallah, 2002, Long-term outcome in acute myelogenous leukemia autografted with mafosfamide-purged marrow in a single institution: adverse events and incidence of secondary myelodysplasia, Bone Marrow Transplant, 30, 15, 10.1038/sj.bmt.1703586
Wadleigh, 2003, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation, Blood, 102, 1578, 10.1182/blood-2003-01-0255
Toor, 2000, Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation, Bone Marrow Transplant, 26, 315, 10.1038/sj.bmt.1702490
Butt, 2003, Autografting as a risk factor for persisting iron overload in long-term survivors of acute myeloid leukaemia, Bone Marrow Transplant, 32, 909, 10.1038/sj.bmt.1704244
Watson, 2004, Adverse impact of bone marrow transplantation on quality of life in acute myeloid leukaemia patients; analysis of the UK Medical Research Council AML 10 Trial, Eur J Cancer, 40, 971, 10.1016/S0959-8049(03)00628-2
Zittoun, 1997, Quality of life in patients with acute myelogenous leukemia in prolonged first complete remission after bone marrow transplantation (allogeneic or autologous) or chemotherapy: a cross-sectional study of the EORTC-GIMEMA AML 8A trial, Bone Marrow Transplant, 20, 307, 10.1038/sj.bmt.1700888
Hsu, 2003, Survival-weighted health profile for long-term survivors of acute myelogenous leukemia, Qual Life Res, 12, 503, 10.1023/A:1025043113819
Wellisch, 1996, Bone marrow transplantation vs. high-dose cytorabine-based consolidation chemotherapy for acute myelogenous leukemia. A long-term follow-up study of quality-of-life measures of survivors, Psychosomatics, 37, 144, 10.1016/S0033-3182(96)71581-5
Delaunay, 2003, Prognosis of in(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup, Blood, 102, 462, 10.1182/blood-2002-11-3527
Farag, 2002, Isolated trisomy of chromosomes 8, 11, 13 and 21 is an adverse prognostic factor in adults with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B 8461, Int J Oncol, 21, 1041
Ferrant, 1997, Karoytype in acute myeloblastic leukemia: prognostic significance for bone marrow transplantation in first remission: a European Group for Blood and Marrow Transplantation Study, Blood, 90, 2931
Frassoni, 2000, Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation, Lancet, 355, 1393, 10.1016/S0140-6736(00)02137-1
Gale, 2005, No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials, Blood, 106, 3658, 10.1182/blood-2005-03-1323
Jourdan, 1997, Early allogeneic transplantation favorably influences the outcome of adult patients suffering from acute myeloid leukemia. Societe Francaise de Greffe de Moelle (SFGM), Bone Marrow Transplant, 19, 875, 10.1038/sj.bmt.1700761
Kebriaei, 2005, Impact of disease burden at time of allogeneic stem cell transplantation in adults with acute myeloid leukemia and myelodysplastic syndromes, Bone Marrow Transplant, 35, 965, 10.1038/sj.bmt.1704938
Marcucci, 2005, Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): A Cancer and Leukemia Group B Study, J Clin Oncol, 23, 5705, 10.1200/JCO.2005.15.610
Ogawa, 2004, Impact of cytogenetics on outcome of stem cell transplantation for acute myeloid leukemia in first remission: a large-scale retrospective analysis of data from the Japan Society for Hematopoietic Cell Transplantation, Int J Hematol, 79, 495, 10.1532/IJH97.03166
Schoch, 2003, AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases, Blood, 102, 2395, 10.1182/blood-2003-02-0434
Wahlin, 2002, Improved outcome in adult acute myeloid leukemia is almost entirely restricted to young patients and associated with stem cell transplantation, Eur J Haematol, 68, 54, 10.1034/j.1600-0609.2002.00562.x
Wheatley, 1999, A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial, Br J Haematol, 107, 69, 10.1046/j.1365-2141.1999.01684.x
Cahn, 1995, Autologous bone marrow transplantation for first remission acute myeloblastic leukemia in patients older than 50 years: a retrospective analysis of the European Bone Marrow Transplant Group, Blood, 85, 575, 10.1182/blood.V85.2.575.575
Slovak, 2000, Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study, Blood, 96, 4075, 10.1182/blood.V96.13.4075
Fung, 2003, A long-term follow-up report on allogeneic stem cell transplantation for patients with primary refractory acute myelogenous leukemia: impact of cytogenetic characteristics on transplantation outcome, Biol Bone Marrow Transplant, 9, 766, 10.1016/j.bbmt.2003.08.004
Lee, 2004, Adult patients with t(8;21) acute myeloid leukemia had no superior treatment outcome to those without t(8;21): a single institution's experience, Ann Hematol, 83, 218
Schlenk, 2003, Risk-adapted postremission therapy in acute myeloid leukemia: results of the German multicenter AML HD93 treatment trial, Leukemia, 17, 1521, 10.1038/sj.leu.2403009
Nguyen, 2002, A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup, Blood, 99, 3517, 10.1182/blood.V99.10.3517
Wong, 2005, Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation, Biol Blood Marrow Transplant, 11, 108, 10.1016/j.bbmt.2004.10.008
Mehta, 2003, Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?, Bone Marrow Transplant, 32, 157, 10.1038/sj.bmt.1704119
Slovak, 1995, Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post bone marrow transplantation: a Southwest Oncology Group study (SWOG-8612), Leukemia Res, 19, 381, 10.1016/0145-2126(94)00162-4
Gale, 1995, Impact of cytogenetic abnormalities on outcome of bone marrow transplants in acute myelogenous leukemia in first remission, Bone Marrow Transplant, 16, 203
Baldus, 2003, BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study, Blood, 102, 1613, 10.1182/blood-2003-02-0359
Dohner, 2005, Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations, Blood, 106, 3740, 10.1182/blood-2005-05-2164
Frohling, 2002, Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm, Blood, 100, 4372, 10.1182/blood-2002-05-1440
Frohling, 2004, CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: Prognostic relevance and analysis of cooperating mutations, J Clin Oncol, 22, 624, 10.1200/JCO.2004.06.060
Marcucci, 2005, Overexpression of the ETS-related gene, ERG, predicts a worse outcome in acute myeloid leukemia with normal karyotype: a Cancer and Leukemia Group B Study, J Clin Oncol, 23, 9234, 10.1200/JCO.2005.03.6137
Rombouts, 2004, Relation between CXCR-4 expression, Flt3 mutations, and unfavorable prognosis of adult acute myeloid leukemia, Blood, 104, 550, 10.1182/blood-2004-02-0566
Rombouts, 2001, Improved prognostic significance of cytokine-induced proliferation in vitro in patients with de novo acute myeloid leukemia of intermediate risk: Impact of internal tandem duplication in the Flt3 gene, Leukemia, 15, 1046, 10.1038/sj.leu.2402157
Schnittger, 2005, Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype, Blood, 106, 3733, 10.1182/blood-2005-06-2248
Thiede, 2006, Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML), Blood, 107, 4011, 10.1182/blood-2005-08-3167
Thiede, 2002, Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis, Blood, 99, 4326, 10.1182/blood.V99.12.4326
Whitman, 2001, Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: A Cancer and Leukemia Group B Study, Cancer Res, 61, 7233
Casanovas, 2003, Immunological classification of acute myeloblastic leukemias: relevance to patient outcome, Leukemia, 17, 515, 10.1038/sj.leu.2402821
Perea, 2005, Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients, Leukemia Res, 29, 1109, 10.1016/j.leukres.2005.02.015
Raspadori, 2001, CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis, Leukemia, 15, 1161, 10.1038/sj.leu.2402174
Repp, 2003, Immunophenotyping is an independent factor for risk stratification in AML, Cytometry Part B: Clin Cytometry, 53B, 11, 10.1002/cyto.b.10030
Spoo, 2007, CXCR4 is a prognostic marker in acute myelogenous leukemia, Blood, 109, 786, 10.1182/blood-2006-05-024844
Schlenk, 2006, Gene mutations as predictive markers for postremission therapy in younger adults with normal karyotype AML, ASH Ann Meet Abstr, 108, 4
Schaich, 2004, Rapid risk-profiling including fast donor search within a multi-center trial allows for early allogeneic stem cell transplantation during aplasia in patients with high-risk acute myeloid leukemia, Blood, 104, 2767, 10.1182/blood.V104.11.2767.2767
Davies SM RN, Weisdorf DJ. Feasibility and timing of unrelated donor identification for patients with ALL. Bone Marrow Transplant. 1996;17:734-740.